Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Volunteer Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693
View directory record Official record
Conditions
Healthy Volunteer, Hepatic Impairment
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

NCT00918606
View directory record Official record
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
LIPO-102
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Interhemispheric Interactions Associated With Performance of Voluntary Movements in Patients With Stroke Motor Disability

NCT00029718
View directory record Official record
Conditions
Cerebrovascular Accident, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortical Excitability in Obsessive-Compulsive and Related Disorders

NCT00029068
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

NCT02922933
View directory record Official record
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
entinostat, Omeprazole, Famotidine
Drug · Dietary Supplement
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

NCT05545306
View directory record Official record
Conditions
Obesity, Normal Physiology, Healthy Volunteers
Interventions
+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fasting, -50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein, -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

NCT06103877
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1163, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 21, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

NCT07225114
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions
contrast agent perflutren lipid, Ultrasound Imaging
Drug · Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanical Coring to Achieve Directional Skin Tightening

NCT04910945
View directory record Official record
Conditions
Skin Tightening, Healthy Volunteers
Interventions
VENUS AIME (RoboCor)
Device
Lead sponsor
Venus Concept
Industry
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Los Altos, California • San Jose, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

NCT01014650
View directory record Official record
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

NCT00925574
View directory record Official record
Conditions
Psoriasis
Interventions
CNTO 1959; Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers

NCT01172509
View directory record Official record
Conditions
Autism
Interventions
R-baclofen
Drug
Lead sponsor
Gonzalez-Heydrich, Joseph, M.D.
Individual
Eligibility
18 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Consistency of StaphVAX Manufacturing Lots

NCT00211991
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 21, 2026, 8:59 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004
View directory record Official record
Conditions
Healthy Volunteer, Psoriasis
Interventions
ABBV-547, ABBV-547 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers

NCT01112787
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam, Vehicle Foam, Sodium Laural Sulfate, Distilled Water
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

NCT05323708
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bmab 1000, Prolia®
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
28 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 21, 2026, 8:59 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

ACE393-103 Vaccination Challenge Study

NCT00859716
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ACE393, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction

NCT02817984
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acellular Adipose Tissue (AAT)
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders

NCT00001362
View directory record Official record
Conditions
Amnesia, Dementia, Healthy, Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles

NCT00692029
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Kentucky
Other
Eligibility
12 Years to 15 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 21, 2026, 8:59 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Wisconsin Brain Donor Program

NCT00585572
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2050
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 8:59 PM EDT